Table 1.
Studies on adjuvant chemoradiotherapy.
| Author | N | Type of Malignancy | Treatment group | Treatment group protocol | Control group | Response | Benefit | Study Design |
|---|---|---|---|---|---|---|---|---|
| Bhatia13 | 125 | Ampullary Carcinoma | Chemoradiation n=29 | RT 50.4 Gy with concurrent 5-FU | Only surgery n=96 | OS 3.4 yr vs 1.6 yr in those with positive LN status | Yes (if node +ve) | Retrospective |
| Sikora12 | 113 (104 alive r afte surgery) | Ampullary Carcinoma | Chemoradiation n=49 | RT 50.4 Gy with concurrent 5-FU | Only surgery n=55 | No significant OS and median survival difference | No | Retrospective |
| Palta14 | 137 | Ampullary Carcinoma | Chemoradiation Adjuvant n=43 | RT 50.4 Gy with concurrent Chemotherapy | Only surgery n=76 | LC 88% vs 55%, | Yes | Retrospective |
| Lee20 | 39 | Ampullary Carcinoma | Chemoradiation n=13 | RT 48.7 Gy with concurrent 5-FU | Only surgery n=26 | OS 55% DFS 54% | Yes (if node +ve) | Retrospective |
| Krishnan15 | 96 | Ampullary Carcinoma | Chemoradiation n=54 | RT 50.4 Gy with concurrent 5-FU (52%) and Cepacetabine (43%) | Only surgery n=42 | 35.2 months with CRT vs 16.5 months with only surgery | Yes (if T3/T4) | Retrospective |
| Kim21 | 118 | Ampullary Carcinoma | Chemoradiation n=41 | RT 40 Gy with 5-FU split course | Only surgery n=77 | mproved LC in ICRT group | Yes (especially if node +ve) | Retrospective |
| Narang22 | 186 | Ampullary Carcinoma | Chemoradiation n=66 | RT median dose 50.4 Gy with 5-FU | Only surgery n=120 | Median OS 39.9 months | Yes (if node +ve) | Retrospective |
| Zhou17 | 111 | Ampullary Carcinoma | Chemoradiation n=50 | Rt median dose 50.4 Gy with 5-FU or Capecitabine | Only surgery n=61 | 33.4 months median OS with CRT vs 36.2 months with surgery alone (not statistically significant) | No | Retrospective |
| Willet23 | 17 (high risk features | Ampullary Carcinoma at presentation) | Radiation n=12 | na | Only surgery n=5 | Improved local control (not statistically significant) | No | Retrospective |
| Mehta | na | Ampullary Carcinoma | Chemoradiation n=12 (patients with high risk features) | RT median dose 45 Gy with 5-FU | na | Median survival 34 months and Actuarial Overall survival 89% | Yes (if +ve LN status, large tumor size, poor histology, neurovascular invasion) | Retrospective |
| Al-Jumayli et al.18 | 45 | Ampullary Carcinoma | Chemoradiation n=5 Chemotherapy n=13 | na | Only surgery n=27 | Median overall survival of the cohort is 30 months | No statistically significant difference in PFS and OS between the surgery vs CRT or chemotherapy group | Singleet center retrospective |